Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
JAK Inhibitors in Cutaneous T-Cell Lymphoma: Potential Benefits, Risks, and Emerging Data
Description
The talk reviewed the JAK-STAT pathway and how JAK inhibitors block cytokine signaling by preventing STAT phosphorylation, with different agents varying in selectivity and toxicity, especially hematologic effects from JAK2 inhibition. The speaker explained that JAK-STAT dysregulation is seen in cutaneous T-cell lymphoma (CTCL), including activating JAK mutations, increased STAT3 activity, and associations with advanced disease and large cell transformation, making the pathway an attractive therapeutic target. Early clinical data and case reports suggest some activity of agents such as ruxolitinib, golidocitinib, and seralutinib, with biomarker-selected patients—those with JAK mutations or STAT3 upregulation—appearing more likely to respond. The speaker also discussed topical JAK inhibition, including a patient whose lesions cleared with topical ruxolitinib and an ongoing phase 2 pilot study of topical tofacitinib at MD Anderson. At the same time, concerns remain about whether JAK inhibitors can unmask or worsen lymphoma, though many reported cases are confounded by prior immune suppression and unclear baseline diagnoses. Additional issues include thrombotic risk, infections, uncertainty about the best disease stage and formulation to treat, and the need for more data to identify which CTCL subgroups benefit most. The talk concluded that JAK inhibitors are promising but still investigational in CTCL, and patients receiving them should be closely monitored with repeat biopsy if progression is unclear.
View moreConclusions
- JAK inhibitors show meaningful activity in selected cutaneous T-cell lymphoma patients, but responses appear to vary by subtype and disease biology.
- Biomarker-defined patients, especially those with JAK or STAT pathway alterations, may be more likely to benefit from JAK inhibition.
- The evidence that JAK inhibitors directly cause CTCL or worsen it is inconclusive, because many reported cases are heavily confounded by prior immune suppression or pre-existing but unrecognized lymphoma.
- Some patients with CTCL, including mycosis fungoides and other subtypes, can improve substantially with JAK inhibitors, including topical approaches in localized disease.
- Topical JAK inhibition may be a promising option for skin-limited CTCL symptoms or residual patches, but it still needs formal study.
- JAK inhibitors are not yet a one-size-fits-all treatment for CTCL, and the best agent, route, and stage of disease for use remain uncertain.
- Because advanced CTCL patients may already be at higher risk for thrombosis and infections, safety monitoring is essential when JAK inhibitors are used.
- When CTCL worsens during JAK inhibitor therapy, repeat biopsy and careful reassessment are important to distinguish progression from unmasking of previously present lymphoma.
- Overall, JAK inhibitors are best viewed as potentially useful but still investigational tools in CTCL, requiring better patient selection and more clinical data.
- Sardana et al. Expert Rev Clin Pharmacol. 2023 Apr;16(4):279-295.
- Virtanen et al. Nat Rev Rheumatol. 2024 Oct;20(10):649-665.
- Vahabi et al. Cancers (Basel) 2024 Feb 21;16(5):861.
- Yumeen et al. Blood Adv. 2020 May 26;4(10):2213-2226.
- Ni et al. Cancers 2025, 17(4), 568.
- Karagianni et al., PLoS ONE 2021, 16, e0248298.
- Chen et al., Int. Immunopharmacol. 2024, 130, 111717.
- Bui et al., JAAD Case Reports.
- Mo et al., SAGE Open Medical Case Reports.
- Porpacyz et al. Blood. 2018 Aug 16;132(7):694-706.
- Pemmaraju et al. Blood. 2019 May 23;133(21):2348-2351.
- Huen et al. EORTC presentation 2024.